Zhifei Biologics

Chongqing Zhifei Biological Products Co., Ltd. was established in 2002, and is a biopharmaceutical enterprise integrating R&D, production, sales, distribution, and import/export of vaccines and biological products. Its registered capital is RMB 2,393,789,747, and total assets are RMB 45.937 billion. In 2024, it generated revenue of RMB 26.07 billion and paid taxes of RMB 5.089 billion. In the first half of 2025, revenue was RMB 4.919 billion with taxes of RMB 767 million. Cumulative taxes paid exceed RMB 28 billion. The Zhifei system (including Zhirui Investment) employs over 10,000 people. In September 2010, the company was listed on the Shenzhen Stock Exchange, becoming the first private vaccine enterprise listed on the ChiNext board. It has 6 subsidiaries and 2 associated companies. Adhering to the corporate tenet of "social benefits first, corporate benefits second" and the core values of "six firsts, six seconds", the company is committed to the mission of "preventing undiseased, curing diseased, and safeguarding human health", striving to become a leading biopharmaceutical enterprise. In R&D, the company adopts an innovation strategy of "independent R&D as the mainstay, collaborative R&D as a supplement, and investment incubation as a complement", and adheres to the development approach of "internationalization of project sources, precision in project selection, pipelining of project development, and localization of project production". It has constructed a comprehensive three-dimensional R&D platform and participated in more than 60 major projects including the National Major New Drug Creation Special Project. It has established three R&D and production bases in Beijing, Anhui, and Chongqing, and multiple R&D centers in Beijing, Shanghai, and other locations. Currently, the company has announced 34 R&D projects in progress, built an eight-category product matrix covering meningococcal, pneumococcal, and enteric vaccines, and established nine technology platforms, including genetic recombination, multi-combination multivalent, mRNA vaccine, and human diploid cell line platforms. The recombinant novel coronavirus vaccine (CHO cell) developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences was included in the Ministry of Science and Technology's key special project on "public safety risk prevention and emergency technical equipment", becoming the first internationally approved recombinant subunit COVID-19 vaccine, contributing positively to the prevention and control of the pandemic. The company's tuberculosis dual products have been launched sequentially; EC has been recommended by the World Health Organization (WHO) for the diagnosis of tuberculosis infection, enabling precise screening of Mycobacterium tuberculosis infection, while Weika has good preventive effects for high-risk populations and latent TB infection and also effective adjuvant therapy for active TB, making a significant impact on the fight against tuberculosis. At the same time, the company is expanding in the biomedical and health industries, deepening presence in oncology, autoimmune diseases, metabolic diseases, neurodegenerative diseases, and cardiovascular diseases, forming a three-dimensional development platform of "prevention + treatment". In March 2025, the company incorporated Chenan Biologics into the listed company, further deepening and expanding its R&D layout, extending business from vaccines to metabolic diseases, and formally entering the therapeutic biopharmaceutical field, opening new prospects for the company's "cure existing diseases" strategy. In marketing, the company has established a comprehensive and in-depth service network, providing continuous, efficient, and comprehensive quality services to 31 provinces, autonomous regions, and municipalities directly under the central government across the country, including more than 300 prefecture-level cities, over 2,600 district and county areas, and more than 30,000 primary health service sites (township vaccination points and community clinics). By self-building a cold chain system compliant with national GSP requirements, the company ensures seamless cold chain for vaccine storage and transportation. Through refrigerated vehicles equipped with real-time temperature monitoring systems and remote automatic alarm capabilities, it delivers vaccine products in high quality to various disease prevention and control centers. After more than two decades of development, the company has been recognized by the community. Its chairman was ranked 9th in Forbes China's 2021 Best CEO List, received the State Council Special Allowance, the National Advanced Individual in Fighting the COVID-19 Pandemic in the Private Economy, the Fifth Outstanding Builder of Socialism with Chinese Characteristics, and other awards. The company was selected into the 2025 Fortune China 500, the 2022 Forbes Global 2000, the TOP 10 global vaccine companies, the 2021 China Private Enterprise Social Responsibility Excellent Case by the All-China Federation of Industry and Commerce, ranked first among 22 national excellent cases, and listed in the China Top 500 Private Enterprises. It has received honors such as the People's Enterprise Social Responsibility Award, the 2023 China Manufacturing Listed Companies Social Responsibility Five-Star Gold Award, the National Advanced Enterprise in Pandemic Response, the National Double-Strength Hundred-Good Party Organization of Non-Public Enterprises, the National Contract-Abiding and Credit-Worthy Enterprise, the National Commercial Integrity Pilot Enterprise, the China Capital Annual Conference A-share Best Listed Companies Top 20, and the Chongqing May Day Labor Award.